Book a demo

Company intelligence

Avalo Therapeutics

Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs.

Biotechnology
Chesterbrook, US
53 employees
Founded 2011
5 public signals

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo's lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.

Verified activity

Signals from Avalo Therapeutics

5 published signals

Find the companies already in motion.

Customize signals around your market, buyers, competitors, and investment thesis.

© 2026 SeedOpsCompany intelligence.

SeedOps.